Medtech company Theraclion obtains €8.5 million in R&D funding from OSEO
The €8.5 million in funding comes as a direct, €3.5 million grant and €5 million in reimbursable advances. In all, €6.9 million of the total amount will be attributed to Theraclion, with €1.6 million going to SuperSonic Imagine. After €500,000 in 2005 and €1.3 million in 2007, this is the third time that OSEO has provided Theraclion with financial support.
“We are particularly proud to see that OSEO has given our company a vote of confidence by awarding significant funding for the third time running. We shall pursue our clinical trials (the interim results of which are very convincing) and prepare the forthcoming commercialization of our products. We are the only company in the world to use ultrasound and our "UNIS" method in the treatment of hyperparathyroidism and our strategy is also to explore new clinical applications to broaden our field of opportunities,” says Ismaël Nujurally, CEO, Theraclion.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.